Journal of Immunology Research / 2015 / Article / Tab 2

Research Article

A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells

Table 2

Dose- and DAR-dependent in vitro cytotoxicity of SPDP-based ADCs.

IC50  ± SE (nM)IC50  ± SE (nM)IC50  ± SE (nM)

ONC1,469 ± 44.50503.2 ± 21.67674.5 ± 99.5
huRFB4 IgG>500>500>500
SPDP-based 162 kDa ADC 1 : 1260.0>284ND
SPDP-based 174 kDa ADC 2 : 10.68 ± 0.302.20 ± 2.07>390
SPDP-based 186 kDa ADC 3 : 10.08 ± 0.020.14 ± 0.02 >335

The concentration required to inhibit cell viability by 50% relative to buffer-treated control cells (IC50) was determined from semilogarithmic plots in which viability as percentage of control was plotted versus the tested protein concentration. IC50 values are expressed as mean ± SE and are derived from at least two independent experiments each performed in triplicate. ND: not determined.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.